申请人:——
公开号:US20030158219A1
公开(公告)日:2003-08-21
A compound of the formula:
1
or a pharmaceutically acceptable salt, ester or ether thereof, wherein R
1
through R
12
are independently hydrogen or the like; X
1
and X
2
are independently CH
2
or the like; R
13
is hydrogen or the like; or R
12
and R
13
taken together with three ring atoms of the quinoline ring separating said substituents form a heterocyclic ring; R
14
and R
15
are hydrogen or the like or these groups taken together form oxo; and the dotted line represents a single or double bond. These compounds are ligands for ORL-1 receptor and especially are antagonists for said receptor.
该化合物的结构式为:1或其药用可接受的盐、酯或醚,其中R1到R12独立地是氢或类似物;X1和X2独立地是CH2或类似物;R13是氢或类似物;或者R12和R13与喹啉环的三个环原子一起形成杂环环;R14和R15是氢或类似物,或这些基团一起形成氧化物;虚线代表单键或双键。这些化合物是ORL-1受体的配体,特别是该受体的拮抗剂。